KRRO korrobio.com: Enterprise Value to EBITDA Ratio
Korro Bio, Inc. (KRRO) is developing advanced genome editing methods, leveraging alliances with major pharma behemoths to strengthen its M&A potential. The company's operations are tied to venture cycles and scientific breakthroughs rather than macroeconomics. The business is currently focused on autonomous preclinical research, and the EV/EBITDA price action chart, which serves as confirmation of the market valuation, recorded a value of 0.00.
KRRO (korrobio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
- financial results and valuation multiples details:
KRRO - Net Income|Future Profit Korro Bio, Inc.|KRRO - Business Payback Period|Future Price to Earnings Korro Bio|KRRO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio|KRRO - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Korro Bio|KRRO - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months korrobio.com|KRRO - Earnings per share growth rate in current year|Earnings growth forecast for next year Korro Bio, Inc.
Summary company analysis:Korro Bio, Inc KRRO
Assessing the resilience of Korro Bio, Inc. (KRRO) to market downturns requires an analysis of its ability to service obligations. A narrow specialization in RNA editing increases the company's dependence on the outcome of clinical trials. The EV/EBITDA ratio for this capital-intensive business compares the total enterprise value with operating profit, excluding the impact of taxes and debt structure. The stability of this metric confirms either a fundamental balance of value or a stagnation in innovative development.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA: EV/EBITDA Multiple|CRSP (CRISPR Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT - Company Value to EBITDA|Twist Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation WVE|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|Total Company Value to Operating Income Before Depreciation Ratio Taysha Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|EV/EBITDA Multiple meiragtx.com MGTX|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SLDB (Solid Biosciences Inc)|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PacBio Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|Company Value to EBITDA designtx.com DSGN|EV/EBITDA Multiple RCKT|4DMT - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|PRQR - EV/EBITDA Multiple|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Sangamo Therapeutics Inc. (SGMO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|Company Value to EBITDA Metagenomi Therapeutics MGX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|GBIO (generationbio.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|Business Value to Operating Income Before Depreciation XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Phio Pharmaceuticals|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|TransCode Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APDN|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|singulargenomics.com (OMIC) - Company Value to EBITDA|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO: EV/EBITDA Multiple|TCON - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
